UNSPSC 51401604: Tiapride hydrochloride

This classification denotes an anti-dyskinesia agent C15H24N2O4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25N106WEDO, chemically known as benzamide, n-(2-(diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)-, hydrochloride (1:1), but more generally known as tiapride hydrochloride, which bears US NIH Compound Identifier 5702214. European Medicines Agency schedules Tiapride hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04854MIG.

Most nations, for tariff and trade purposes, schedule tiapride hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, TIAPRIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)CCNC(=O)C1CC(CCC1OC)S(=O)(=O)C.CL.

UNSPSC 51401604 Tiapride hydrochloride is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and drug-related supplies procured by health agencies, counties, and cooperative purchasing alliances. The recent opportunities tagged to this code show state and local buyers purchasing naloxone and safe drug deactivation systems for emergency response, generic pharmaceuticals and over-the-counter products through multistate cooperative frameworks, and exploring direct-to-manufacturer prescription programs to manage pharmacy costs and supply chain efficiency. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon). The work spans product procurement with quarterly or ongoing delivery requirements, compliance with FDA and drug supply chain security standards, and in some cases direct vendor relationships with authorized pharmaceutical wholesalers.

Recent opportunities show activity concentrated in Texas, Minnesota, Florida, and Oregon. Seminole County, Florida released IFB 60459723LAS on June 30, 2026 (due July 26, 2023) seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive sealed bidding with quarterly deliveries to the county community health building and a two-year initial term with one-year renewal option. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 on January 20, 2026 (responses due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to state and local facilities, with awards effective July 1, 2026, requiring vendors to work through three authorized wholesalers and meet cGMP and DSCSA certification. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 as an exploratory market intelligence solicitation regarding direct-to-manufacturer prescription programs and vendor capacity to establish relationships outside traditional pharmacy benefit managers and wholesalers, with no award values or formal competitive timeline specified at the information-gathering stage.